Celldex Therapeutics, Inc.

NasdaqCM:CLDX Stock Report

Market Cap: US$1.7b

Celldex Therapeutics Management

Management criteria checks 2/4

Celldex Therapeutics' CEO is Anthony Marucci, appointed in May 2003, has a tenure of 21.58 years. total yearly compensation is $8.36M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 0.061% of the company’s shares, worth $1.01M. The average tenure of the management team and the board of directors is 8.5 years and 11.9 years respectively.

Key information

Anthony Marucci

Chief executive officer

US$8.4m

Total compensation

CEO salary percentage8.6%
CEO tenure21.6yrs
CEO ownership0.06%
Management average tenure8.5yrs
Board average tenure11.9yrs

Recent management updates

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Jun 07
Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Recent updates

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Jun 07
Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jun 05
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jul 07
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Apr 21
An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Feb 27
Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Sep 07
We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder

Jul 21

Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement

Jul 14

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

May 25
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Feb 03
Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Celldex: Pipeline Of Drug Candidates Is Worth A Look

Feb 01

Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers

Sep 23

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Sep 15
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

CEO Compensation Analysis

How has Anthony Marucci's remuneration changed compared to Celldex Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$154m

Jun 30 2024n/an/a

-US$150m

Mar 31 2024n/an/a

-US$145m

Dec 31 2023US$8mUS$721k

-US$141m

Sep 30 2023n/an/a

-US$125m

Jun 30 2023n/an/a

-US$113m

Mar 31 2023n/an/a

-US$119m

Dec 31 2022US$5mUS$693k

-US$112m

Sep 30 2022n/an/a

-US$106m

Jun 30 2022n/an/a

-US$100m

Mar 31 2022n/an/a

-US$77m

Dec 31 2021US$6mUS$669k

-US$71m

Sep 30 2021n/an/a

-US$72m

Jun 30 2021n/an/a

-US$66m

Mar 31 2021n/an/a

-US$64m

Dec 31 2020US$3mUS$644k

-US$60m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$46m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$1mUS$619k

-US$51m

Sep 30 2019n/an/a

-US$50m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$50m

Dec 31 2018US$1mUS$608k

-US$151m

Sep 30 2018n/an/a

-US$146m

Jun 30 2018n/an/a

-US$165m

Mar 31 2018n/an/a

-US$177m

Dec 31 2017US$2mUS$598k

-US$93m

Compensation vs Market: Anthony's total compensation ($USD8.36M) is above average for companies of similar size in the US market ($USD5.51M).

Compensation vs Earnings: Anthony's compensation has increased whilst the company is unprofitable.

CEO

Anthony Marucci (62 yo)

21.6yrs

Tenure

US$8,361,844

Compensation

Mr. Anthony S. Marucci, M.B.A., has been the Chief Executive Officer and President of Celldex Therapeutics Inc. since September 2008. He co-founded Celldex Therapeutics Inc. in 2004. Mr. Marucci served as...

Leadership Team

NamePositionTenureCompensationOwnership
Anthony Marucci
Founder21.6yrsUS$8.36m0.061%
$ 1.0m
Tibor Keler
Founder21.6yrsUS$3.42m0.011%
$ 185.0k
Sam Martin
Senior VP7.4yrsUS$2.95m0.042%
$ 707.0k
Margo Heath-Chiozzi
Senior Vice President of Regulatory Affairs7.2yrsUS$2.94m0.020%
$ 336.4k
Diane Young
Senior VP & Chief Medical Officer5.5yrsUS$2.97m0.026%
$ 430.3k
Joseph Schlessinger
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Sarah Cavanaugh
Senior Vice President of Corporate Affairs & Administration7.5yrsno data0.0028%
$ 46.7k
Freddy Jimenez
Senior VP & General Counsel3.9yrsUS$2.17m0.053%
$ 891.5k
Ronald Pepin
Chief Business Officer & Senior VP13.4yrsno datano data
Elizabeth Crowley
Chief Product Development Officer & Senior VP10.4yrsUS$1.18m0.014%
$ 228.2k
Richard Wright
Chief Commercial Officer & Senior VP9.4yrsUS$563.17k0.031%
$ 523.7k

8.5yrs

Average Tenure

62yo

Average Age

Experienced Management: CLDX's management team is seasoned and experienced (8.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Anthony Marucci
Founder16yrsUS$8.36m0.061%
$ 1.0m
Joseph Schlessinger
Co-Founder & Member of Scientific Advisory Board3.3yrsno datano data
Harry Penner
Independent Director27.9yrsUS$371.19k0.0042%
$ 70.2k
Herbert Conrad
Independent Director16.8yrsUS$364.94k0.0039%
$ 64.4k
Louis Weiner
Member of Scientific Advisory Boardno datano datano data
James Marino
Independent Director7.8yrsUS$377.44k0.0033%
$ 55.4k
Karen Shoos
Independent Chair of the Board of Directors23.6yrsUS$385.77k0.0042%
$ 70.1k
Carl June
Member of Scientific Advisory Boardno datano datano data
Michel Nussenzweig
Member of Scientific Advisory Boardno datano datano data
Marc Rothenberg
Member of Scientific Advisory Boardno datano datano data
Keith Brownlie
Independent Director7.5yrsUS$373.27k0.0010%
$ 16.7k
Cheryl Cohen
Independent Director2.5yrsUS$367.02k0%
$ 0

11.9yrs

Average Tenure

72yo

Average Age

Experienced Board: CLDX's board of directors are seasoned and experienced ( 11.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:22
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Celldex Therapeutics, Inc. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason WittesAegis Capital Corporation
Jonathan AschoffBrean Capital
Kristen KluskaCantor Fitzgerald & Co.